Price Elasticities of Pharmaceuticals in a Value-Based-Formulary Setting

Kai Yeung, Anirban Basu, Ryan N. Hansen, Sean D. Sullivan

NBER Working Paper No. 22308
Issued in June 2016
NBER Program(s):Health Care, Health Economics

Ever since the seminal RAND Health insurance experiment (HIE) was conducted, most health care services, including pharmaceuticals, are deemed to be price inelastic with price elasticities of demand (PED) close to -0.20. However, most studies of PED exploit natural experiments that change demand prices for multiple components of health care. Consequently, these experiments usually do not produce estimates for the true own-price elasticities of demand but rather composite own-price elasticities that are driven by concomitant price changes to their substitutes and complements. Hence, an estimate of price elasticity is expected to vary based on the setting in which it was estimated, and likely not be applicable to other settings. In this work, exploiting a natural experiment of exogenous policy implementation of a value-based formulary (VBF) that was designed based on drug-specific incremental cost-effectiveness ratios, we estimate price elasticities of pharmaceuticals within a VBF design, formally accounting for the nature of composite elasticities that such a setting would generate. We also calculate welfare effects of such a policy using a consumer surplus approach. We show theoretically that VBF designs can increase dispersion of price elasticities of demand among pharmaceutical products compared to their true own-price elasticities and affect their magnitude based on direction of price change. Aligning these PEDs with value VBF is also likely to produce positive welfare effects. We estimate an overall PED for pharmaceuticals to be -0.16, close to the estimate of RAND HIE. However, we see substantial dispersion of PED across the VBF tiers ranging from -0.09 to -0.87 with trends aligned with the levels of value as reflected by the cost-effectiveness ratio (p<0.001). The net welfare increase was $147,000 for the cohort or $28 per member over the post-policy year. Further experimentations of VBF designs with alternative cost-effectiveness thresholds, copayment levels and value-definitions could be quite promising for improving welfare.

download in pdf format
   (472 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w22308

Published: Kai Yeung & Anirban Basu & Ryan N. Hansen & Sean D. Sullivan, 2018. "Price elasticities of pharmaceuticals in a value based-formulary setting," Health Economics, vol 27(11), pages 1788-1804.

Users who downloaded this paper also downloaded* these:
Besanko, Dranove, and Garthwaite w22353 Insurance and the High Prices of Pharmaceuticals
Einav, Finkelstein, and Polyakova w22277 Private Provision of Social Insurance: Drug-specific Price Elasticities and Cost Sharing in Medicare Part D
Lavetti and Simon w22338 Strategic Formulary Design in Medicare Part D Plans
Danzon, Towse, and Mestre-Ferrandiz w18593 Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
Danzon and Ketcham Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us